NCT04539496View on ClinicalTrials.gov

A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

402

Participants

Timeline

Start Date

May 22, 2018

Primary Completion Date

July 31, 2023

Study Completion Date

December 31, 2025

Conditions
Metastasis Solid TumorsAdvanced Breast Cancer
Interventions
DRUG

XZP-3287

"* 20-560 mg QD, oral~* 240-480 mg BID, oral"

DRUG

XZP-3287;Letrozole;Anastrozole;Fulvestrant

XZP-3287: 360 mg BID, oral; Letrozole: 2.5 mg QD, oral; Anastrozole: 1 mg QD, oral; Fulvestrant: 500 mg intramuscular injection on C1D1, C1D15, the first day of each subsequent cycle (28 days a cycle)

DRUG

XZP-3287

480 mg BID, oral

Trial Locations (1)

100000

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Sihuan Pharmaceutical Holdings Group Ltd.

INDUSTRY

NCT04539496 - A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors | Biotech Hunter | Biotech Hunter